Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview

Q Medicine

Clinical Lipidology Pub Date : 2014-10-01 DOI:10.2217/clp.14.37

Jessica S Ross, S. Russo, Georgia C Chavis, L. Cowart

引用次数: 11

Abstract

Abstract Climbing obesity rates have contributed to worldwide increases in obesity-associated diseases, including the metabolic syndrome and Type 2 diabetes mellitus (T2DM). Sphingolipids, an important class of structural and signaling lipids, have emerged as key players in the development and pathogenesis of insulin resistance and T2DM. More specifically, sphingolipids have been demonstrated to play integral roles in lipotoxicity and other aspects of pathogenesis in T2DM, although the cellular mechanisms by which this occurs and by which sphingolipid metabolism is dysregulated in T2DM remain under investigation. This review summarizes current knowledge of sphingolipid metabolism and signaling in key organs and tissues affected by T2DM, including the pancreas, adipose tissue, skeletal muscle, cardiovascular system and liver, and highlights areas that ripe for future investigation.

查看原文本刊更多论文

2型糖尿病细胞功能障碍的鞘脂调节:系统综述

肥胖率的上升导致全球范围内肥胖相关疾病的增加，包括代谢综合征和2型糖尿病(T2DM)。鞘脂是一类重要的结构脂和信号脂，在胰岛素抵抗和T2DM的发展和发病机制中起着关键作用。更具体地说，鞘脂已被证明在2型糖尿病的脂肪毒性和其他发病机制中起着不可或缺的作用，尽管这种作用发生的细胞机制以及鞘脂代谢失调在2型糖尿病中仍在研究中。本文综述了T2DM影响的关键器官和组织(包括胰腺、脂肪组织、骨骼肌、心血管系统和肝脏)鞘脂代谢和信号传导的现有知识，并强调了未来研究的成熟领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.